SG151253A1 - Combination vaccines with low dose of hib conjugate - Google Patents

Combination vaccines with low dose of hib conjugate

Info

Publication number
SG151253A1
SG151253A1 SG200901653-6A SG2009016536A SG151253A1 SG 151253 A1 SG151253 A1 SG 151253A1 SG 2009016536 A SG2009016536 A SG 2009016536A SG 151253 A1 SG151253 A1 SG 151253A1
Authority
SG
Singapore
Prior art keywords
hib
vaccines
conjugate
low dose
combination
Prior art date
Application number
SG200901653-6A
Other languages
English (en)
Inventor
Mario Contorni
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32117706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG151253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of SG151253A1 publication Critical patent/SG151253A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG200901653-6A 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate SG151253A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0405787.3A GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines

Publications (1)

Publication Number Publication Date
SG151253A1 true SG151253A1 (en) 2009-04-30

Family

ID=32117706

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200901653-6A SG151253A1 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate

Country Status (13)

Country Link
US (2) US20090208526A1 (enExample)
EP (1) EP1725258B1 (enExample)
JP (2) JP4954056B2 (enExample)
CN (2) CN102028944B (enExample)
AT (1) ATE480257T1 (enExample)
BR (1) BRPI0508813B8 (enExample)
CA (1) CA2559996C (enExample)
DE (1) DE602005023422D1 (enExample)
DK (1) DK1725258T3 (enExample)
GB (1) GB0405787D0 (enExample)
RU (1) RU2435609C2 (enExample)
SG (1) SG151253A1 (enExample)
WO (1) WO2005089794A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1296715T2 (sl) * 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2201961B1 (en) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunogenic composition
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
WO2009133408A2 (en) * 2008-05-01 2009-11-05 Arecor Limited Protein formulation
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
CN102655879B (zh) * 2009-12-16 2016-03-09 印度血清研究所 疫苗组合物
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
CN103796683A (zh) 2011-04-21 2014-05-14 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
AU2013338153B2 (en) * 2012-10-29 2018-06-21 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
MX2020000441A (es) 2017-07-18 2020-08-17 Serum Inst Of India Pvt Ltd Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma.
CN110251667A (zh) * 2018-05-11 2019-09-20 武汉博沃生物科技有限公司 一种免疫组合制剂及其制备方法和应用
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN118903397A (zh) * 2024-10-12 2024-11-08 成都迈科康生物科技有限公司 GloboH六糖、linker化合物、蛋白偶联物及免疫原性组合物在治疗或抑制上皮性肿瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
EP1082965B1 (en) * 1995-06-23 2009-06-10 GlaxoSmithKline Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
SI1296715T2 (sl) 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva

Also Published As

Publication number Publication date
JP2008150397A (ja) 2008-07-03
CN102028944B (zh) 2013-12-04
CA2559996A1 (en) 2005-09-29
WO2005089794A2 (en) 2005-09-29
US20120107346A1 (en) 2012-05-03
CN102028944A (zh) 2011-04-27
CA2559996C (en) 2014-08-05
GB0405787D0 (en) 2004-04-21
BRPI0508813B1 (pt) 2019-05-21
US9259460B2 (en) 2016-02-16
RU2006136212A (ru) 2008-04-27
RU2435609C2 (ru) 2011-12-10
CN1968711B (zh) 2011-01-05
EP1725258B1 (en) 2010-09-08
WO2005089794A3 (en) 2006-03-09
ATE480257T1 (de) 2010-09-15
EP1725258A2 (en) 2006-11-29
BRPI0508813A (pt) 2007-08-07
JP4954056B2 (ja) 2012-06-13
BRPI0508813B8 (pt) 2021-05-25
CN1968711A (zh) 2007-05-23
US20090208526A1 (en) 2009-08-20
DE602005023422D1 (de) 2010-10-21
JP2007529503A (ja) 2007-10-25
DK1725258T3 (da) 2010-11-01

Similar Documents

Publication Publication Date Title
SG151253A1 (en) Combination vaccines with low dose of hib conjugate
ES2164251T5 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
UY26801A1 (es) Composición de vacuna
EP3170508A1 (en) Vaccine formulations
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
EP2682127A1 (en) Vaccine
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
MX2008013993A (es) Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
JP2015531389A5 (enExample)
RU2015106745A (ru) Иммуногенные композиции
IL107387A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
WO2013171661A2 (en) Adjuvant formulations and methods
ES2365557T5 (es) Vacunas de combinación de Poliovirus inactivado
Wu et al. Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
Carson et al. Reimmunization after CHAPTER
HK1241718A1 (zh) 疫苗制剂
HK1185001A (en) Vaccine formulations
SA96170157B1 (ar) تركيب لقاح composition vaccine يشتمل على مولد مضاد متعدد سكريد مقترن antigen conjugated polsaccharide يتم امتزازه على فوسفات الألومنيوم aluminum phosphate
MXPA97009732A (en) Vaccine comprising a conjugate of antigen depolisacarido protein carrier and protein carrier li